Therapeutic potential of ALKB homologs for cardiovascular disease

• Main Authors: Ming-Zhu Xiao, Jia-Ming Liu, Cui-Ling Xian, Keng-Yu Chen, Zhong-Qiu Liu, Yuan-Yuan Cheng
• Format: Article
• Language: English
• Published: Elsevier 2020-11-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Cardiovascular diseases; ALKB homologs; RNA demethylation; DNA demethylation; Oxidative stress; Therapy
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332220308386

Cardiovascular diseases (CVDs) are the leading causes of human death. Recently, ALKB homologs, including ALKBH1−8 and FTO, have been found to have a variety of biological functions, such as histone demethylation, RNA demethylation, and DNA demethylation. These functions may regulate the physiological and pathological processes of CVDs, including inflammation, oxidative stress, cell apoptosis, and mitochondrial, endothelial, and fat metabolism dysfunction. In the present review, we summarize the biological functions of ALKB homologs and the relationship between the ALKB homologs and CVDs. Importantly, we discuss the roles of ALKB homologs in the regulation of oxidative stress, inflammation, autophagy, and DNA damage in CVDs, as well as the practical applications of ALKB homologs inhibitors or agonists in treating CVDs. In conclusion, the ALKBH family might be a promising target for CVDs therapy.